MARKET

MAZE

MAZE

Maze Therapeutics
NASDAQ
26.05
-0.16
-0.61%
After Hours: 25.69 -0.36 -1.38% 19:30 09/25 EDT
OPEN
26.23
PREV CLOSE
26.21
HIGH
27.79
LOW
25.42
VOLUME
925.61K
TURNOVER
--
52 WEEK HIGH
53.65
52 WEEK LOW
21.95
MARKET CAP
1.45B
P/E (TTM)
-10.3764
1D
5D
1M
3M
1Y
5Y
1D
Maze Therapeutics Price Target Maintained With a $110.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $110 Price Target
Benzinga · 1d ago
Maze Therapeutics Price Target Announced at $50.00/Share by Citigroup
Dow Jones · 2d ago
Maze Therapeutics Initiated at Buy by Citigroup
Dow Jones · 2d ago
Citigroup Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $50
Benzinga · 2d ago
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE), Viking Therapeutics (VKTX) and Aytu BioScience (AYTU)
TipRanks · 2d ago
Maze Therapeutics Price Target Maintained With a $48.00/Share by Wedbush
Dow Jones · 2d ago
More
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Webull offers Maze Therapeutics, Inc. stock information, including NASDAQ: MAZE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MAZE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MAZE stock methods without spending real money on the virtual paper trading platform.